EBOS Group Limited (ASX: EBO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

EBOS Group Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • EBOS Group Limited (ASX: EBO)
    Latest News

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Earnings Results

    This ASX 200 healthcare stock crashed 14% to 4-year low. Here's what happened

    Spooked investors sold off their shares.

    Read more »

    Teen standing in a city street smiling and throwing sparkling gold glitter into the air.
    52-Week Highs

    11 ASX 200 stocks streaking to multi-year highs today

    The benchmark ASX 200 is in the green and these 11 stocks are setting new price records.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    Healthcare Shares

    Which ASX 200 healthcare share will pay the best dividend yield in 2025?

    Earnings season is underway and dividend announcements are on investors' minds.

    Read more »

    A woman holds her finger to the side of her lips in contemplation as she looks upwards to an array of graphic images of light bulbs above her head, one of which is on and glowing.
    Investing Strategies

    'Stock is oversold': 5 ASX shares to buy now before resurgence

    Check out these Best Idea gems from Morgans in the chaos of reporting season.

    Read more »

    A man reacts with surprise when her see a bargain price on his phone.
    Earnings Results

    3 ASX 300 shares going gangbusters on stellar earnings results

    These ASX 300 shares are well into the green today amid their full-year reports.

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why ASX, Baby Bunting, Bowen Coking Coal, and EBOS shares are sinking today

    These ASX shares are falling heavily on Tuesday.

    Read more »

    a man smiles broadly as he holds up five fingers on one hand and two fingers on the other hand.
    Broker Notes

    7 more ideas for buying ASX shares this reporting season: expert

    The superpowers might be jostling for the new world order and the global economy might be on the brink, but…

    Read more »

    a person stands on top of a mountain with hands raised above their head gazing on an amazing sunrise over the landscape and above the clouds.
    52-Week Highs

    5 ASX All Ords shares cracking new 52-week highs on Tuesday

    Are your investments trading at their highest point in more than 12 months today?

    Read more »

    A man looks surprised as a woman whispers in his ear.
    Share Market News

    5 profitable ASX shares you probably have never heard of

    This one might broaden your horizons.

    Read more »

    Four people on the beach leap high into the air.
    Healthcare Shares

    This ASX All Ordinaries share shrugged off the red to reach a new 52-week high today

    We take a look at an All Ordinaries share that outperformed the index, and itself, today.

    Read more »

    Three healthcare workers standing together and smiling.
    Earnings Results

    Here are 3 ASX healthcare share results you might have missed

    Regis Healthcare, EBOS and Neuren Pharmaceuticals are three ASX healthcare shares that just posted results. Here is what you need…

    Read more »

    A group of business people pump the air and cheer.
    Share Market News

    Here are the top 10 ASX shares today

    These are your biggest gainers to end the week.

    Read more »

    Frequently Asked Questions

    Yes, EBOS Group has historically paid two partially franked shareholder dividends a year.

    EBOS Group generally pays its shareholder dividends in March and September. 

    Yes, EBOS has a dividend reinvestment plan to allow shareholders to reinvest all or part of their dividends.

    EBOS Group Ltd listed on the ASX on 6 September 2013.

    EBO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About EBOS Group Limited

    EBOS Group Ltd (ASX: EBO) is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.

    EBOS Group also operates an animal health product wholesale, manufacturing, and retail business, as well as providing third-party logistics services.

    The vast majority of the company's revenue derives from its services to community pharmacies and institutional healthcare providers, which accounts for about 80% of revenue. Its Australian operations similarly contribute around 80% of its total revenue.

     

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Dec 2025 Coline McConville Buy 1,000 $24,347
    On-market trade.
    27 Nov 2025 Julie Tay Buy 1,000 $28,000
    On-market trade. NZ$
    10 Nov 2025 Matthew Muscio Buy 3,800 $108,563
    On-market trade. NZ$
    30 Oct 2025 Tracey Batten Buy 2,728 $67,531
    On-market trade.
    21 Oct 2025 Mark Bloom Buy 1,500 $37,647
    On-market trade.
    07 Oct 2025 Julie Tay Buy 2,000 $52,000
    On-market trade.
    24 Sep 2025 Stuart McLauchlan Issued 56 $1,623
    Dividend Reinvestment Plan (DRP). NZ$
    23 Sep 2025 Elizabeth(Liz) Coutts Buy 3,000 $87,903
    On-market trade. NZ$
    22 Sep 2025 Stuart McLauchlan Buy 1,000 $29,200
    On-market trade. NZ$
    04 Sep 2025 Matthew Muscio Expiry 15,828 $443,975
    As advised by the company. Lapse of performance rights
    17,859 performance rights
    30 May 2025 Mark Bloom Buy 2,000 $68,800
    On-market trade.
    13 May 2025 Elizabeth(Liz) Coutts Issued 1,364 $49,990
    Issue of securities. NZ$, retail offer
    13 May 2025 Stuart McLauchlan Issued 95 $3,481
    Issue of securities. NZ$, retail offer
    13 May 2025 Tracey Batten Issued 272 $9,968
    Issue of securities. NZ$ retail offer
    21 Mar 2025 Stuart McLauchlan Issued 39 $1,442
    Dividend Reinvestment Plan (DRP). NZ$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Elizabeth(Liz) Mary Coutts Non-Executive DirectorNon-Executive Chairman Nov 2013
    Ms Coutts is a former Chair of Skellerup Holdings Limited, Ports of Auckland Limited, Meritec Group, Industrial Research, Life Pharmacy Limited, former director of Air New Zealand Limited, the Health Funding Authority, Sanford Limited, the Yellow Group of Companies and Tennis Auckland Region Incorporated, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac) and Marsh New Zealand Advisory Board, former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand, a former president of the Institute of Directors Inc and former Chief Executive of the Caxton Group of Companies. She is a member of the Risk Committee.
    Mr Mark Alan Bloom Non-Executive Director Sep 2022
    Mr Bloom is a former director of Pacific Smiles Group Limited and Abacus Property Group. Mark has over 35 years of experience as a finance executive. Prior to this, he was Deputy Group CFO of Westfield Group for 11 years. Mark has also held several senior finance roles, including being CFO and executive director for insurance and financial services companies Liberty Life, South Africa and Manulife Financial, Canada. Mark is a member of the Audit and Risk Committee.
    Mr Stuart McLauchlan Non-Executive Director Jul 2019
    Mr McLauchlan is a partner of GS McLauchlan & Co. He is currently chairman of Scott Technology Ltd, ADInstruments Ltd, Cargill Hotel 2022 Ltd, Otago Community Hospice and Woods Solutions. He is the director of Argosy Properties Ltd and Scenic Hotels Group, as as several private companies. He is also a governor of the New Zealand Sports Hall of Fame. He was formerly a chairman of Pharmac and UDC Finance, member of the Marsh New Zealand Advisory Board, and director of Ngai Tahu Tourism Ltd. He is Chairman of the Risk Committee.
    Mr Matthew Peter Muscio Non-Executive Director Jan 2025
    Mr Muscio's career spans more than 25 years in the medical device industry with the last 15 years in medical technology distribution under both public and private ownership models. Matt has been a board member for the Medical Technology Association of Australia from 2017 to 2023 and currently serves as a non-executive board member for Tetrous Inc, a regenerative medicine company.
    Dr Tracey Leigh Batten Non-Executive Director Jul 2021
    Dr Batten is currently a non-executive director of Medibank Private Limited and Nanosonics Limited. She was previously Chair of the Accident Compensation Corporation, a non-executive director of National Institute of Water and Atmospheric Research, Abano Healthcare Group Limited and various other healthcare related research institutes, charities and industry and government bodies. During her executive career she was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health and CEO of Dental Health Services Victoria. Mark is a member of the Risk Committee.
    Ms Julie Tay Non-Executive Director May 2023
    Ms Tay is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She has over 30 years of experience in international executive and non-executive roles across consumer healthcare, medical devices and digital healthcare. Julie was most recently Senior Vice President and Managing Director, Asia Pacific and member of the global Executive Management Committee for Align Technology. Prior to this, she was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson.
    Ms Coline McConville Non-Executive Director Feb 2025
    Ms McConville has 20 years of governance experience advising a range of organizations operating in different countries and industries. Her expertise includes advising across acquisitive portfolio companies, complex distribution organizations, capital intensive businesses, consumer driven vertically integrated and global service companies. During her executive career, Ms McConville was Chief Executive Officer and Chief Operating Officer for Clear Channel Communications (now iHeartMedia Inc.) and a management consultant with McKinsey and Co and LEK Consulting. She is currently a director of 3i Group and a member of the Supervisory Board of Germany-based Tui AG. Her previous directorships include Kings Cross Central General Partnership, TUI Travel, UTV Media, Travis Perkins, Fevertree Drinks, Inchcape, Wembley National Stadium, Shed Media, Halifax and HBOS.
    Grant Viney CEO Animal Care
    -
    Kristine James CEO Medical Technology
    -
    Brett Barons CEO Symbion & Healthcare Distribution
    -
    Alistair Gray Chief Financial Officer
    -
    Mithran Naiker Chief Information Officer
    -
    Martin Krauskopf Chief Strategy and Corporate Development Officer
    -
    David Lewis EGM
    -
    Simon Bunde EGM Strategic Operations ESG and Innovation
    -
    Jacinta McCarthy Executive General Manager Human Resources
    -
    Janelle Cain General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    JP Morgan Nominees Australia Limited 25,085,843 12.34%
    HSBC Nominees (New Zealand) Limited NZCSD 14,677,082 7.22%
    HSBC Custody Nominees (Australia) Limited 13,682,865 6.73%
    BNP Paribas Nominees (NZ) Limited NZCSD 13,500,892 6.64%
    Custodial Services Limited 12,678,532 6.24%
    Sybos Holdings PTE Limited 9,957,825 4.90%
    Forsyth Barr Custodians Limited 8,616,830 4.24%
    HSBC Nominees (New Zealand) Limited A/C State Street NZCSD 8,506,099 4.19%
    Tea Custodians Limited Client Property Trust Account NZCSD 8,317,469 4.09%
    JPMorgan Chase Bank NA NZ Branch-Segregated Clients Acct NZCSD 7,772,261 3.82%
    Citibank Nominees (New Zealand) Limited NZCSD 7,202,785 3.54%
    Accident Compensation Corporation NZCSD 6,391,154 3.15%
    HSBC Nominees A/C NZ Superannuation Fund Nominees Limited NZCSD 5,480,889 2.70%
    FNZ Custodians Limited 4,197,368 2.07%
    JBWere (NZ) Nominees Limited 2,804,413 1.38%
    ANZ Wholesale Australasian Share Fund NZCSD 2,655,236 1.31%
    Citicorp Nominees Pty Limited 2,612,454 1.29%
    New Zealand Depository Nominee Limited 2,499,353 1.23%
    Generate Kiwisaver Public Trust Nominees Limited <NZCSD> 2,020,090 0.99%
    Simplicity Nominees Limited NZCSD 1,862,793 0.91%

    Profile

    since

    Note